Longitude Prime Partners, LLC - Feb 6, 2023 Form 3 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
10%+ Owner
Signature
Longitude Prime Partners, LLC, By: /s/ Patrick Enright, managing member
Stock symbol
VERA
Transactions as of
Feb 6, 2023
Transactions value $
$0
Form type
3
Date filed
2/8/2023, 06:21 PM
Previous filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VERA Class A Common Stock 1.71M Feb 6, 2023 Held by Longitude Prime Fund, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Not included on this Form 3 are 3,429,927 shares of Class A Common Stock held by Longitude Venture Partners IV, L.P ("LVP IV"). LVP IV, Longitude Capital Partners IV, LLC ("LCP IV"), Patrick G. Enright and Juliet Tammenoms Bakker have separately filed a Form 4 in connection with the acquisition of the shares of Class A Common Stock described in this Form.
F2 The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Remarks:

Mr. Enright, a managing member of LPP and LCP IV, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.